126 related articles for article (PubMed ID: 26050355)
1. Chemotherapy-induced thrombocytopenia and clinical bleeding in patients with gynecologic malignancy.
Hashiguchi Y; Fukuda T; Ichimura T; Matsumoto Y; Yasui T; Sumi T; Ishiko O
Eur J Gynaecol Oncol; 2015; 36(2):168-73. PubMed ID: 26050355
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.
Hashiguchi Y; Kasai M; Fukuda T; Ichimura T; Yasui T; Sumi T
Anticancer Drugs; 2015 Nov; 26(10):1054-60. PubMed ID: 26267078
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer.
Goldberg GL; Gibbon DG; Smith HO; DeVictoria C; Runowicz CD; Burns ER
J Clin Oncol; 1994 Nov; 12(11):2317-20. PubMed ID: 7964946
[TBL] [Abstract][Full Text] [Related]
4. Conservative management of chemotherapeutic-induced thrombocytopenia in women with gynecologic cancers.
Fanning J; Hilgers RD; Murray KP; Bolt K; Aughenbaugh DM
Gynecol Oncol; 1995 Nov; 59(2):191-3. PubMed ID: 7590471
[TBL] [Abstract][Full Text] [Related]
5. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.
Elting LS; Rubenstein EB; Martin CG; Kurtin D; Rodriguez S; Laiho E; Kanesan K; Cantor SB; Benjamin RS
J Clin Oncol; 2001 Feb; 19(4):1137-46. PubMed ID: 11181679
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
Vadhan-Raj S; Verschraegen CF; Bueso-Ramos C; Broxmeyer HE; Kudelkà AP; Freedman RS; Edwards CL; Gershenson D; Jones D; Ashby M; Kavanagh JJ
Ann Intern Med; 2000 Mar; 132(5):364-8. PubMed ID: 10691586
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-related hypersensitivity reaction in Japanese patients with gynecologic malignancy.
Kitada K; Hashiguchi Y; Fukuda T; Yoshida H; Ichimura T; Matsumoto Y; Yasui T; Sumi T; Ishiko O
Eur J Gynaecol Oncol; 2012; 33(3):252-4. PubMed ID: 22873092
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion.
Heubel-Moenen FCJI; Henskens YMC; Verhezen PWM; Wetzels RJH; Schouten HC; Beckers EAM
J Thromb Haemost; 2019 Jul; 17(7):1073-1084. PubMed ID: 31033178
[TBL] [Abstract][Full Text] [Related]
9. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007.
Wu Y; Aravind S; Ranganathan G; Martin A; Nalysnyk L
Clin Ther; 2009; 31 Pt 2():2416-32. PubMed ID: 20110050
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
[TBL] [Abstract][Full Text] [Related]
11. Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors.
Dutcher JP; Schiffer CA; Aisner J; O'Connell BA; Levy C; Kendall JA; Wiernik PH
Cancer; 1984 Feb; 53(3):557-62. PubMed ID: 6692260
[TBL] [Abstract][Full Text] [Related]
12. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders.
Wardrop D; Estcourt LJ; Brunskill SJ; Doree C; Trivella M; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Jul; (7):CD009733. PubMed ID: 23897323
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.
Kuter DJ
Haematologica; 2022 Jun; 107(6):1243-1263. PubMed ID: 35642485
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy.
Cantor SB; Elting LS; Hudson DV; Rubenstein EB
Cancer; 2003 Jun; 97(12):3099-106. PubMed ID: 12784347
[TBL] [Abstract][Full Text] [Related]
15. Dose reductions and delays: limitations of myelosuppressive chemotherapy.
Cairo MS
Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):21-31. PubMed ID: 11033835
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors.
Hitron A; Steinke D; Sutphin S; Lawson A; Talbert J; Adams V
J Oncol Pharm Pract; 2011 Dec; 17(4):312-9. PubMed ID: 20823048
[TBL] [Abstract][Full Text] [Related]
18. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors.
Elting LS; Cantor SB; Martin CG; Hamblin L; Kurtin D; Rivera E; Vadhan-Raj S; Benjamin RS
Cancer; 2003 Mar; 97(6):1541-50. PubMed ID: 12627519
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant human interleukin-3 (rhIL-3) on persisting chemotherapy-induced thrombocytopenia.
Meden H; Fock M; Kuhn W
Anticancer Drugs; 1994 Aug; 5(4):483-6. PubMed ID: 7949256
[TBL] [Abstract][Full Text] [Related]
20. Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin.
Saccullo G; Malato A; Raso S; Santoro M; Zammit V; Casuccio A; Siragusa S
Am J Hematol; 2012 Apr; 87(4):388-91. PubMed ID: 22374861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
